Harrow has entered into an agreement with Samsung Bioepis for the U.S. commercial rights to two ophthalmology biosimilars, ...

Samsung Bioepis Co., Ltd. ("Samsung Bioepis") announced today that the company has entered into a license, development and ...

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it has entered into a ...

Included in the agreement are ranibizumab-nuna 0.05 mL injection (BYOOVIZ), referencing LUCENTIS (ranibizumab), and aflibercept-yszy 0.05 mL injection (OPUVIZ), referencing EYLEA (aflibercept).

This systematic review comprehensively summarizes treatment approaches for all types of age-related macular degeneration (AMD ...

Treatments for uveitic macular edema, including systemic and local options, were among the topics debated at the Congress on Controversies in Ophthalmology.

Age-related macular degeneration (AMD) remains a leading cause of vision loss, but new therapies are reshaping its treatment.

In early research, OCU410ST, a gene therapy for Stargardt disease, demonstrated slowed lesion growth by 48% at the 12-month follow-up in evaluable treated eyes.

Age-related macular degeneration (AMD) remains a leading cause of vision loss globally, with significant advancements in ...

Canadian study reveals diabetic patients taking GLP-1 medications face twice the risk of eye problems, with longer exposure increasing danger of macular degeneration.

Washington University researchers found that raising a molecule called ApoM helps eye cells sweep away harmful cholesterol deposits linked to age-related macular degeneration, potentially ...

Fixing problems with cholesterol metabolism might help slow or prevent a common cause of age-related vision loss, a new WashU Medicine study in mice has shown.